Exhibit 10.3


 


ASSIGNMENT,
ASSUMPTION AND AMENDMENT AGREEMENT


 


THIS ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT
(this “Agreement”) is made and entered into as of December 20, 2022, by and among (i) COVA Acquisition
Corp., a Cayman Islands exempted company (the “SPAC”), (ii) ECARX Holdings Inc., a Cayman Islands
exempted company (the “Company”), and (iii) Continental Stock Transfer & Trust Company, a New
York limited purpose trust company, as warrant agent (the “Warrant Agent”). Capitalized terms used but not otherwise
defined herein shall have the respective meanings assigned to such terms in the Warrant Agreement (as defined below) (and if such term
is not defined in the Warrant Agreement, then the Merger Agreement (as defined below)).


 


RECITALS


 


WHEREAS,
SPAC and the Warrant Agent are parties to that certain Warrant Agreement, dated as of February 4, 2021 (as amended, including without
limitation by this Agreement, the “Warrant Agreement”), pursuant to which the Warrant Agent agreed to act as
the SPAC’s warrant agent with respect to the issuance, registration, transfer, exchange, redemption and exercise of (i) warrants
to purchase ordinary shares of the SPAC issued in SPAC’s initial public offering (“IPO”) (the “Public
Warrants”), (ii) warrants to purchase ordinary shares underlying the units of SPAC acquired by COVA Acquisition Sponsor
LLC (the “Sponsor”), in a private placement concurrent with the IPO (the “Private Placement Warrants”),
and (iii) warrants to purchase ordinary shares issuable to the Sponsor or an affiliate of the Sponsor or certain officers and directors
of SPAC upon conversion of up to $1,000,000 of working capital loans (the “Working Capital Warrants” and together
with the Public Warrants and the Private Placement Warrants, the “Warrants”);


 


WHEREAS,
on May 26, 2022, (i) SPAC, (ii) the Company, (iii) Ecarx Temp Limited, an exempted company limited by shares incorporated under
the laws of the Cayman Islands and a direct wholly owned subsidiary of the Company (“Merger
Sub 1”), and (iv) Ecarx&Co Limited, an exempted company limited by shares incorporated under the laws of the
Cayman Islands and a direct wholly owned subsidiary of the Company (“Merger
Sub 2”), entered into that certain Agreement and Plan of Merger (as it may be amended after the date hereof, the
 “Merger Agreement”);


 


WHEREAS,
pursuant to the Merger Agreement, upon the consummation of the transactions contemplated thereby (the
 “Closing”), among other matters and subject to the terms and conditions thereof, (a) Merger Sub 1 will
merge with and into SPAC (the “First Merger”), with SPAC being the surviving entity, and (b) immediately
following the First Merger and as part of the same overall transaction as the First Merger, SPAC, in its capacity as the surviving
entity of the First Merger, will merge with and into Merger Sub 2 (the “Second
Merger” and together with the First Merger, collectively, the “Mergers”),
with Merger Sub 2 being the surviving entity, and as a result of which, among other matters, (i) Merger Sub 2, in its capacity
as the surviving entity of the Second Merger, shall remain a wholly-owned subsidiary of the Company and (ii) each SPAC Class A
Ordinary Share (which includes each SPAC Class A Ordinary Share (A) issued in connection with the SPAC Class B Conversion and (B)
held as a result of the Unit Separation) immediately prior to the effective time of the First Merger (the “Effective
Time”) shall automatically be cancelled and cease to exist in exchange for the right to receive one newly issued,
fully paid and non-assessable class A ordinary shares, par value $0.000005 per share, of the Company (together with any other
securities of the Company or any successor entity issued in consideration of (including as a stock split, dividend or distribution)
or in exchange for any of such securities, the “Company Class A Ordinary Shares”), all upon the terms and
subject to the conditions set forth in the Merger Agreement and in accordance with the provisions of applicable law;


 






     


     


    

 


WHEREAS,
upon consummation of the Mergers, as provided in the Merger Agreement and Section 4.5 of the Warrant Agreement, each of the issued
and outstanding Warrants will no longer be exercisable for SPAC Ordinary Shares (as defined in the Merger Agreement) but instead will
be exercisable (subject to the terms and conditions of the Warrant Agreement as amended hereby) for the same number of Company Class A
Ordinary Shares at the same exercise price per share; and


 


WHEREAS,
the Company Class A Ordinary Shares constitute an Alternative Issuance as defined in said Section 4.5 of the Warrant Agreement;


 


WHEREAS,
all references to “Ordinary Shares” in the Warrant Agreement (including all Exhibits thereto) shall mean the Company Class
A Ordinary Shares;


 


WHEREAS,
the board of directors of SPAC has determined that the consummation of the transactions contemplated by the Merger Agreement will constitute
a Business Combination (as defined in the Warrant Agreement); and


 


WHEREAS,
in connection with the Mergers, SPAC desires to assign all of its right, title and interest in the Warrant Agreement to the Company, and
the Company wishes to accept such assignment and assume all the liabilities and obligations of SPAC under the Warrant Agreement with the
same force and effect as if the Company were initially a party to the Warrant Agreement.


 


NOW,
THEREFORE, in consideration of the premises and the mutual promises herein made, and in consideration of the representations,
warranties and covenants herein contained, and intending to be legally bound hereby, the parties hereto agree as follows:


 


1.              Assignment and Assumption; Consent.


 


(a)           Assignment and Assumption. SPAC hereby assigns to the Company all of SPAC’s right, title and interest in and to the
Warrant Agreement and the Warrants (each as amended hereby) as of the Effective Time. The Company hereby assumes, and agrees to pay, perform,
satisfy and discharge in full, as the same become due, all of SPAC’s liabilities and obligations under the Warrant Agreement and
the Warrants (each as amended hereby) arising from and after the Effective Time with the same force and effect as if the Company were
initially a party to the Warrant Agreement.


 






    2


     


    

 


(b)           Consent.
The Warrant Agent hereby consents to the assignment of the Warrant Agreement and the Warrants by SPAC to the Company and the
assumption by the Company of the SPAC’s obligations under the Warrant Agreement pursuant to Section 1(a) hereof
effective as of the Effective Time, the assumption of the Warrant Agreement and Warrants by the Company from SPAC pursuant to Section 1(a) hereof
effective as of the Effective Time, and to the continuation of the Warrant Agreement and Warrants in full force and effect from and
after the Effective Time, subject at all times to the Warrant Agreement and Warrants (each as amended hereby) and to all of the
provisions, covenants, agreements, terms and conditions of the Warrant Agreement and this Agreement.


 


2.             Amendments to Warrant Agreement. The parties hereto hereby agree to the following amendments to the Warrant Agreement and
acknowledge and agree that the amendments to the Warrant Agreement set forth in this Section 2 (i) are necessary and desirable and do
not adversely affect the rights of the Registered Holders under the Warrant Agreement in any material respect and (ii) are to provide
for the delivery of Alternative Issuance pursuant to Section 4.5 of the Warrant Agreement:


 


(a)           Preamble
and References to the “Company”. The preamble of the Warrant Agreement is hereby amended by deleting “COVA Acquisition
Corp.” and replacing it with “ECARX Holdings Inc.”. As a result thereof, all references to the “Company”
in the Warrant Agreement (including all exhibits thereto) shall be amended such that they refer to the Company rather than SPAC.


 


(b)           Recitals. The recitals on pages one and two of the Warrant Agreement are hereby deleted and replaced in their entirety as
follows:


 


“WHEREAS,
on February 4, 2021, COVA Acquisition Corp. (“COVA”) entered into that certain Private Placement Warrants Purchase Agreement
with COVA Acquisition Sponsor, a Cayman Islands limited liability company, (the “Sponsor”), pursuant to which the Sponsor
agreed to purchase an aggregate of 7,725,000 warrants (or up to 8,875,000 warrants if the Over-allotment Option (as defined below) in
connection with the Public Offering (as defined below) is exercised in full) simultaneously with the closing of the Public Offering (and
the closing of the Over-allotment Option, if applicable) bearing the legend set forth in Exhibit B hereto (the “Private Placement
Warrants”) at a purchase price of $1.00 per Private Placement Warrant; and


 


WHEREAS, in
order to finance COVA’s transaction costs in connection with an intended initial merger, share exchange, asset acquisition, share
purchase, reorganization or similar business combination, involving the Company and one or more businesses, the Sponsor or an affiliate
of the Sponsor or certain of COVA’s officers and directors could, but were not obligated to, loan COVA funds as COVA required, of
which up to $1,000,000 of such loans may be convertible into up to an additional 1,000,000 Private Placement Warrants at a price of $1.00
per Private Placement Warrant (the “Working Capital Warrants”); and


 


WHEREAS,
COVA consummated an initial public offering (the “Public Offering”) of units of COVA’s equity securities, each
such unit comprised of one Class A ordinary share and one-half of one Public Warrant (as defined below) (the
 “Units”) and, in connection therewith, issued and delivered up to 15,007,500 warrants (including up to 1,957,500
warrants subject to the Over-allotment Option) to public investors in the Public Offering (the “Public Warrants” and
together with the Private Placement Warrants and Working Capital Warrants, the “COVA Warrants”). Each whole COVA Warrant
entitles the holder thereof to purchase one Class A ordinary share of COVA for $11.50 per share, subject to adjustment. Only whole
warrants are exercisable; and


 






    3


     


    

 


WHEREAS, COVA
has filed with the Securities and Exchange Commission (the “Commission”) a registration statement on Form S-1, File No. 333-252273 (the
 “Registration Statement”) and prospectus (the “Prospectus”), for the registration, under the Securities Act of
1933, as amended (the “Securities Act”), of the Units, and the Public Warrants and the Class A ordinary shares included in
the Units; and


 


WHEREAS,
on May 26, 2022, (i) SPAC, (ii) the Company, (iii) Ecarx&Co Limited, an exempted company limited by shares incorporated under the
laws of the Cayman Islands and a direct wholly owned subsidiary of the Company (“Merger Sub 1”), and (iv) Ecarx Temp Limited,
an exempted company limited by shares incorporated under the laws of the Cayman Islands and a direct wholly owned subsidiary of the Company
(“Merger Sub 2”), entered into that certain Agreement and Plan of Merger (as it may be amended after the date hereof, the
 “Merger Agreement”) and, as a result, all Class A ordinary shares of COVA shall be exchanged for the right to receive class
A ordinary shares, par value $0.000005 per share, of the Company (“Company Class A Ordinary Shares”); and


 


WHEREAS, pursuant
to the Merger Agreement and Section 4.5 of this Agreement, immediately after the First Effective Time (as defined in the Merger Agreement),
each of the issued and outstanding COVA Warrants will no longer be exercisable for Ordinary Shares but instead will become exercisable
(subject to the terms and conditions of this Agreement) for Company Class A Ordinary Shares (each a “Warrant” and collectively,
the “Warrants”); and


 


WHEREAS, the
Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the
issuance, registration, transfer, exchange, redemption and exercise of the Warrants; and


 


WHEREAS, the
Company desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the
respective rights, limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the Warrants; and


 


WHEREAS, all
acts and things have been done and performed which are necessary to make the Warrants, when executed on behalf of the Company and countersigned
by or on behalf of the Warrant Agent, as provided herein, the valid, binding and legal obligations of the Company, and to authorize the
execution and delivery of this Agreement.


 


NOW, THEREFORE,
in consideration of the mutual agreements herein contained, the parties hereto agree as follows:”


 


(c)           Detachability
of Warrants. Section 2.4 of the Warrant Agreement is hereby deleted and replaced with the following: “[INTENTIONALLY OMITTED]”


 


(d)           Reference to Ordinary Shares. All references to “Ordinary Shares” in the Warrant Agreement (including all Exhibits
thereto) shall mean Company Class A Ordinary Shares.


 






    4


     


    

 


(e)           Reference to Business Combination. All references to “Business Combination” in the Warrant Agreement (including
all Exhibits thereto) shall be references to the transactions contemplated by the Merger Agreement, and references to “the completion
of the Business Combination” and all variations thereof in the Warrant Agreement (including all Exhibits thereto) shall be references
to the closing of the transactions contemplated by the Merger Agreement.


 


(f)            Notices. Section 9.2 of the Warrant Agreement is hereby amended to delete the address of the Company for notices under
the Warrant Agreement and instead add the following address for notices to the Company:


 


	
     

     

    ECARX Holdings Inc.

    16/F, Tower 2, China Eastern Airline Binjiang Center

    277 Longlan Road

    Xuhui District, Shanghai 200041

    People’s Republic of China

    Attention: Tony Chen

    Email: tony.chen@ecarxgroup.com
	
    with a copy (which will not constitute notice) to:

     

    Skadden, Arps, Slate, Meagher & Flom LLP

    c/o 42/F, Edinburgh Tower, The Landmark

    15 Queen’s Road Central

    Hong Kong

    Email: julie.gao@skadden.com

    Attention: Z. Julie Gao

    

    and

    

    Skadden, Arps, Slate, Meagher & Flom LLP

    30/F, China World Office 2

    No. 1, Jian Guo Men Wai Avenue

    Beijing 100004, China

    Email: peter.huang@skadden.com

    Attention: Peter X. Huang



 


3.              Effectiveness.
Notwithstanding anything to the contrary contained herein, this Agreement shall be expressly subject to the occurrence of and only become
effective upon the Closing. In the event that the Merger Agreement is terminated for any reason in accordance with its terms prior to
the Closing, this Agreement and all rights and obligations of the parties hereunder shall automatically terminate and be of no further
force or effect.


 


4.              Miscellaneous.
Except as expressly provided in this Agreement, all of the terms and provisions in the Warrant Agreement are and shall remain in
full force and effect, on the terms and subject to the conditions set forth therein. This Agreement does not constitute, directly or
by implication, an amendment or waiver of any provision of the Warrant Agreement, or any other right, remedy, power or privilege of
any party thereto, except as expressly set forth herein. Any reference to the Warrant Agreement in the Warrant Agreement or any
other agreement, document, instrument or certificate entered into or issued in connection therewith, shall hereinafter mean the
Warrant Agreement as the case may be, as amended by this Agreement (or as such agreement may be further amended or modified in
accordance with the terms thereof). The terms of this Agreement shall be governed by, enforced and construed and interpreted in a
manner consistent with the provisions of the Warrant Agreement, as it applies to the amendments to the Warrant Agreement herein,
including without limitation Section 9 of the Warrant Agreement.


 


[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK;
SIGNATURE PAGES FOLLOW]


 






    5


     


    

 


 


IN
WITNESS WHEREOF, each party hereto has caused this Agreement to be signed and delivered by its respective duly authorized officer
as of the date first above written.


 


	 	SPAC:
	 	 
	 	COVA ACQUISITION CORP.
	 	 
	 	By:	 /s/ Jun Hong Heng
	 	Name: Jun Hong Heng
	 	Title: Chief Executive Officer
	 	 
	 	The Company:
	 	 
	 	ECARX HOLDINGS INC.
	 	 
	 	By:	 /s/ SHEN Ziyu
	 	Name: SHEN Ziyu
	 	Title: Director
	 	 
	 	Warrant Agent:
	 	 
	 	CONTINENTAL STOCK TRANSFER & TRUST COMPANY
	 	 
	 	By:	/s/ Erika Young
	 	Name: Erika Young
	 	Title: Vice President, 12/20/22




 


[Signature Page to Assignment, Assumption and Amendment
Agreement]


  



    6